Free Trial
NASDAQ:IDYA

IDEAYA Biosciences (IDYA) Stock Price, News & Analysis

IDEAYA Biosciences logo
$22.09 +0.17 (+0.78%)
As of 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About IDEAYA Biosciences Stock (NASDAQ:IDYA)

Key Stats

Today's Range
$21.84
$22.32
50-Day Range
$17.10
$22.63
52-Week Range
$13.45
$44.42
Volume
522,894 shs
Average Volume
1.03 million shs
Market Capitalization
$1.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.42
Consensus Rating
Moderate Buy

Company Overview

IDEAYA Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

IDYA MarketRank™: 

IDEAYA Biosciences scored higher than 71% of companies evaluated by MarketBeat, and ranked 901st out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IDEAYA Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 12 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    IDEAYA Biosciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about IDEAYA Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for IDEAYA Biosciences are expected to decrease in the coming year, from ($3.07) to ($3.20) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IDEAYA Biosciences is -6.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IDEAYA Biosciences is -6.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    IDEAYA Biosciences has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about IDEAYA Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    14.39% of the float of IDEAYA Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEAYA Biosciences has a short interest ratio ("days to cover") of 8.
  • Change versus previous month

    Short interest in IDEAYA Biosciences has recently increased by 8.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    IDEAYA Biosciences does not currently pay a dividend.

  • Dividend Growth

    IDEAYA Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.39% of the float of IDEAYA Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEAYA Biosciences has a short interest ratio ("days to cover") of 8.
  • Change versus previous month

    Short interest in IDEAYA Biosciences has recently increased by 8.00%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    IDEAYA Biosciences has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for IDEAYA Biosciences this week, compared to 6 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, IDEAYA Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.50% of the stock of IDEAYA Biosciences is held by insiders.

  • Percentage Held by Institutions

    98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IDEAYA Biosciences' insider trading history.
Receive IDYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDYA Stock News Headlines

A grave, grave error.
Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the key to unlocking technological breakthroughs we once thought were impossible. And it may just be the only thing capable of bringing America back from the brink of recession – despite Washington’s incompetence and addiction to reckless spending. That’s why Elon Musk, Jeff Bezos, Jensen Huang, and even Bill Gates are pouring billions into the infrastructure behind it.
See More Headlines

IDYA Stock Analysis - Frequently Asked Questions

IDEAYA Biosciences' stock was trading at $25.70 on January 1st, 2025. Since then, IDYA shares have decreased by 14.0% and is now trading at $22.09.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) issued its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by $0.07.

IDEAYA Biosciences (IDYA) raised $70 million in an initial public offering on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies served as the underwriters for the IPO.

Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEAYA Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/06/2025
Today
7/03/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IDYA
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$53.42
High Stock Price Target
$68.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+141.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
15 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$274.48 million
Pretax Margin
-4,386.90%

Debt

Sales & Book Value

Annual Sales
$7 million
Price / Cash Flow
N/A
Book Value
$12.25 per share
Price / Book
1.80

Miscellaneous

Free Float
85,392,000
Market Cap
$1.93 billion
Optionable
Optionable
Beta
0.03
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:IDYA) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners